Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 216.00K | 75.00K | 73.00K | 59.00K | 97.00K |
Gross Profit | 108.00K | -306.00K | 64.00K | -64.00K | -171.06K |
EBITDA | -22.49M | -18.70M | -17.85M | -13.60M | -7.91M |
Net Income | -21.75M | -19.56M | -18.56M | -13.78M | -8.30M |
Balance Sheet | |||||
Total Assets | 52.21M | 4.46M | 5.97M | 21.38M | 11.59M |
Cash, Cash Equivalents and Short-Term Investments | 50.87M | 2.48M | 4.06M | 19.77M | 9.80M |
Total Debt | 284.00K | 559.00K | 811.00K | 213.00K | 405.00K |
Total Liabilities | 4.96M | 4.26M | 3.09M | 1.37M | 1.35M |
Stockholders Equity | 47.25M | 202.00K | 2.88M | 20.01M | 10.24M |
Cash Flow | |||||
Free Cash Flow | -19.58M | -18.01M | -15.91M | -13.05M | -7.63M |
Operating Cash Flow | -19.40M | -18.01M | -15.90M | -12.83M | -7.54M |
Investing Cash Flow | -179.00K | -1.00K | -13.00K | -221.00K | -94.00K |
Financing Cash Flow | 68.03M | 16.02M | 0.00 | 22.52M | 1.77M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | $410.04M | ― | -22.95% | ― | 40.88% | -579.73% | |
58 Neutral | $653.45M | ― | -115.47% | ― | ― | ― | |
58 Neutral | £4.95B | 6.56 | -62.36% | 103.85% | 34.03% | 6.31% | |
57 Neutral | $739.87M | ― | -83.24% | ― | -100.32% | -197.69% | |
55 Neutral | $631.82M | ― | 181.41% | ― | 3055.71% | -18.80% | |
47 Neutral | $311.07M | ― | -48.57% | ― | -100.00% | 83.98% | |
45 Neutral | $370.71M | ― | -1869.55% | ― | -60.19% | 56.60% |
On July 9, 2025, Benitec Biopharma announced that the sixth and final subject of Cohort 1 was safely treated with a low dose of BB-301 in their Phase 1b/2a Clinical Treatment Study. Following a positive recommendation from the Data Safety Monitoring Board, the company plans to begin enrolling subjects for Cohort 2 in the fourth quarter of 2025. This development marks a significant step in advancing their gene therapy program, potentially enhancing Benitec’s position in the biotechnology industry and offering hope for stakeholders involved in the treatment of OPMD.
The most recent analyst rating on (BNTC) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Benitec Biopharma stock, see the BNTC Stock Forecast page.